Overall rank by patents
#10,195
of 50,000 tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Synta Pharmaceuticals Corp.
USPTO PatentsView assignee record - 31 granted patents across 11 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
31
Total patents granted
11
CPC technology areas
12.8
Avg claims per patent
-93%
5-year grant velocity
The verdict
According to USPTO PatentsView, Synta ranks #10,195 of 50,000 tracked US assignees by granted-patent volume, with 31 patents across 11 technology areas.
- #10,195
- of 50,000 US assignees by volume
- Top 52%
- by Innovation Score (34.7/100)
- 12.8
- avg claims per patent
- -93%
- grant velocity, last 5 yrs
Portfolio overview
Synta Pharmaceuticals Corp. has been granted 31 US utility patents between 2015 and 2022, placing Synta Pharmaceuticals Corp. at #10,195 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.8 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Synta Pharmaceuticals Corp. is one of the more focused assignees in the PatentsView dataset. By volume, Synta sits between Starmark Pet Products, Inc. (31 patents, rank #10,191) and TECH 21 Licensing Limited (31 patents, rank #10,199) - the closest US assignees by grant volume. The composite Innovation Score of 34.7/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 2 grants, compared with 29 in the 2015–2019 window, a -93% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Synta Pharmaceuticals Corp.'s 12.8 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 11 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Who files at Synta's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Starmark Pet Prod…
Starmark Pet Products, Inc.
31 patents
- Stasher
Stasher, Inc.
31 patents
- Sunasic
SunASIC Technologies, Inc.
31 patents
- Sustainable Energ…
Sustainable Energy Solutions, Inc.
31 patents
- System General
System General Corp.
31 patents
- TA Instruments-wa…
TA Instruments-Waters LLC
31 patents
- Taipei Veterans G…
TAIPEI VETERANS GENERAL HOSPITAL
31 patents
- TECH 21 Licensing
TECH 21 LICENSING LIMITED
31 patents
- Synta Pharmaceuti… ◀
Synta Pharmaceuticals Corp.
31 patents
What this shows Synta holds 31 patents at rank #10,195, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Synta
By rank, the assignees closest to #10,195 in granted patent volume.
- Starmark Pet Products, Inc. #10,191 · 31 patents
- Stasher, Inc. #10,192 · 31 patents
- Sunasic Technologies, Inc. #10,193 · 31 patents
- Sustainable Energy Solutions, Inc. #10,194 · 31 patents
- System General Corp. #10,196 · 31 patents
- TA Instruments-waters Llc #10,197 · 31 patents
- Taipei Veterans General Hospital #10,198 · 31 patents
- TECH 21 Licensing Limited #10,199 · 31 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Synta's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Synta, neither rank-band nor same-CPC leaders (those blocks stay above).
Similar innovation score
Nearest assignees by Innovation Score (35 here).
Synta's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
35 Top 52% higher than 48% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 22 | 71.0% |
| 2016 | 3 | 9.7% |
| 2017 | 3 | 9.7% |
| 2019 | 1 | 3.2% |
| 2021 | 1 | 3.2% |
| 2022 | 1 | 3.2% |
Which technologies does Synta Pharmaceuticals Corp. patent most?
Top 11 of 11 technology areas
Grant record at a glance
Portfolio Volume 31 grants
CPC subclasses 11
Avg. claims / grant 12.8
Velocity -93%
Historical grant data only; it does not rate legal strength or current strategy.
Frequently Asked Questions
Where does Synta Pharmaceuticals Corp. rank among US patent assignees?
According to USPTO PatentsView (2015–2025 granted utility patents), Synta Pharmaceuticals Corp. ranks #10,195 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.
How many patents does Synta Pharmaceuticals Corp. hold?
Synta Pharmaceuticals Corp. holds 31 US utility patents granted between 2015 and 2022, spanning 11 technology areas.
What is Synta Pharmaceuticals Corp.'s Innovation Score?
Synta Pharmaceuticals Corp. has an Innovation Score of 34.7 out of 100 (top 52% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Synta Pharmaceuticals Corp. focus on?
Synta Pharmaceuticals Corp.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 31 patents. Grants appear in 11 CPC subclasses total.
Is Synta Pharmaceuticals Corp.'s patent grant rate increasing or decreasing?
Synta Pharmaceuticals Corp.'s recent grant velocity is -93% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.
What does claim depth mean for Synta Pharmaceuticals Corp.'s patents?
Synta Pharmaceuticals Corp.'s patents average 12.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.
How is the Synta Pharmaceuticals Corp. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Synta's 31 grants land it in the top 52% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Synta ranks #10,195 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.